Solving the $5.3B Patient Recruitment Problem

Author: Mark Wade, Global Practice Leader, TransPerfect Life Sciences

With the patient recruitment market forecasted to reach $5.3 billion by 2030, sponsors can't afford to treat enrollment as an afterthought. Reduce clinical trial delays and regrettable spend with our proven patient recruitment strategies.

patient-recruitment

Challenges in Patient Recruitment

Participant recruitment is constrained by several structural and behavioral bottlenecks that contribute to study delays, including:

  • Icon Analytics 2

Most patients don't know trials exist

88% of participants never discuss their research experience, and 26% of people don't know where trials are conducted.

  • Icon Global Contract

Thousands of trials compete for the same limited participant populations.

Over 60,000 trials are recruiting or have not yet started in the U.S. alone.

  • Icon Progress Bar

One rejection discourages further participation

65% of those who don't qualify for a study don't search for another.

  • Icon QA

Randomization processes and screening introduce high failure rates.

For every 1,000 patients, assuming they don’t have a rare disease, only 10% will actually be randomized.

Why don’t more participants enroll?

61 %

Increase in eligibility criteria

The total number of eligibility criteria for an average Phase III protocol has jumped from 31 to 50 from 2002 to 2012. Source: National Institutes of Health


57 %

Fear side effects

20 %

Fear risks to overall health

13 %

Fear receiving placebo

Planning an AI Strategy

What Works

Successful recruitment programs apply a structured, multi-layered approach rather than relying on a single channel or tactic:

  • Address patient recruitment early, before site activation, rather than treating it as a downstream task
  • Design outreach strategies around real patient behavior and decision patterns
  • Recognize that awareness, eligibility, and enrollment are distinct filtering stages
  • Account for the steep attrition between initial interest and final randomization
  • Treat recruitment as a continuous, measurable process rather than a one-time activity

How TransPerfect Helps

TransPerfect supports patient recruitment through integrated services that address communication, localization, and operational scale across global trials.

  1. Patient-facing content creation and localization to support multilingual outreach
  2. Translation and adaptation of recruitment and study materials
  3. Support for compliant global communications and documentation
  4. Expertise across therapeutic areas and trial phases
Data Security with AI

Your Patient Recruitment Checklist

So how can we maximize our efforts to recruit patients and keep them for the length of the study?

  • Create meaningful, insightful, and informative web landing pages. They must be readily accessible to potential patients, and written in easy-to-understand prose.

  • Patient facing materials must be culturally acceptable. As we recruit patients globally, we must be mindful of the language, culture, and customs of our target market. Insensitivity can do more harm to a brand than good.

  • Any direct mail needs to be created with brevity in mind. Patients receive significant solicitation mail daily. Study information, if not created succinctly, can be dismissed out of hand.

  • Site and Principal Investigator (PI) literature needs to be able to speak to the clinician in a way that appeals to their clinical needs. This is not to be confused with patient-facing materials. Both need to be addressed with a different mindset.

  • Ensure materials are created by teams that understand the disease state primarily. It is not just about graphics and fuzzy animals. The artwork can come later.

  • Ensure that your provider understands more than simply placing social media advertisements. Ensure that there are metrics for success and a methodology to amend and fine-tune the tactic in real time.

  • Have a plan to transport a subject to a site if they are unable to do so on their own. Remove every barrier to enrollment possible.

  • Ensure that there is a plan to retain the subject once the study has begun. Develop a plan to send encouragement and support throughout the entire lifecycle of the study, for years if necessary.

Ready to Recruit Faster and Retain Longer?

Cut enrollment timelines, cost, and reduce dropout rates with targeted patient solutions.

How did you hear about us?
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Related Resources

Considerations for eCOA in Global Clinical Trials

Regulatory Considerations for eCOA Submissions in Global Clinical Trials: What You Need to Know When managing eCOA in clinical trials across multiple countries, translation, linguistic validation, and electronic implementation of Clinical Outcome Assessments (COAs) are key elements to consider. eCOA adds additional steps and timelines to the process, which can often create confusion around regulatory requirements for submissions. In the United States, submissions are ...

Considerations for eCOA in Global Clinical Trials

Veeva RIM TMS Integration Checklist

If your regulatory team is still downloading documents from Veeva Vault, managing translation requests by email, or tracking submissions in spreadsheets, there's a better way. Reduce complexity, close compliance gaps, and shorten your submission cycle times with this ...

The Current State of AI in Translation for Clinical Content

AI is reshaping how clinical trial content gets translated and localized, but in a regulated environment, speed can't come at the cost of accuracy or traceability. This white paper breaks down where AI delivers real value, where human oversight remains essential, and how to ...

The Veeva Vault RIM Translation Integration

Managing multilingual regulatory submissions shouldn't mean chasing files across email threads and re-entering metadata by hand. This playbook breaks down how direct translation integration with Veeva Vault RIM eliminates manual bottlenecks, preserves compliance, and cuts ...

Buyer's Guide: Translation Management Integration with Veeva Vault RIM

Translation bottlenecks, fragmented audit trails, and uncontrolled AI output aren't edge cases in regulatory operations; they're the predictable result of a poorly integrated workflow. This buyer's guide is built for regulatory leaders who need more than a file ...

LifeSci Talks COA Series | Are We Sacrificing Good for Perfect in Clinical Outcome Assessment?

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Stacie Hudgens, Chief Scientific and Strategy Officer at Clinical Outcome Solutions, to discuss whether the field of clinical outcome assessment has started ...

AI Governance in Medical Information: What "Human-in-the-Loop" Actually Requires

These days, you can't have a conversation about AI in life sciences without someone invoking "human-in-the-loop." It's become so expected that leaving it out feels like a red flag—a signal that AI governance hasn't been fully considered. The problem isn't the phrase...